MM-310 delivers a novel taxane and targets EphA2, a tumor marker shown to be overexpressed in several solid tumors including prostate, ovarian, gastric, pancreatic and lung cancer. MM-310 uses Merrimack's proprietary nanotherapeutics delivery platform to provide controlled biodistribution and sustained exposure of a proprietary docetaxel prodrug at the site of the tumor, potentially allowing for improved antitumor activity while lowering exposure in normal tissues and minimizing the hematologic toxicities common with docetaxel or the vascular toxicity associated with a traditional EphA2-targeted antibody drug conjugate (ADC) format. Preclinical data to be presented at the conference include the immunomodulatory effects of MM-310 in combination with a PD-1 inhibitor as well as tolerability and anti-tumor activity data on MM-310 in combination with carboplatin.
Also highlighted at the conference will be preclinical data for MM-141 (istiratumab), a monoclonal bispecific antibody that acts as a tetravalent inhibitor of IGF1-R and HER3, and MM-161, a novel first-in-class pan-FGFR antibody. Merrimack will also present data on several other targeted therapies currently or previously in development.
MM-310: A novel EphA2-targeted nanotherapeutic delivering a proprietary docetaxel prodrug
Istiratumab (MM-141): A monoclonal antibody that acts as a tetravalent inhibitor of PI3K/AKT/mTOR
MM-151: An oligoclonal therapeutic consisting of a mixture of 3 fully human monoclonal antibodies designed to bind and inhibit signaling of the epidermal growth factor receptor (EGFR)
MM-161: A novel first-in-class pan-FGFR antibody
MM-398 (ONIVYDE® (irinotecan liposome injection) or "Nal-IRI"): A novel encapsulation of irinotecan in a liposomal formulation
Merrimack is a biopharmaceutical company based in
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack's strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "hope" and similar expressions. In this press release, Merrimack's forward-looking statements include statements about the potential effectiveness and safety profile of MM-310 and
Merrimack's ability to translate preclinical data into future clinical success. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack's development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, development progress of Merrimack's companion diagnostics, availability of funding sufficient for Merrimack's foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other matters that could affect the availability or commercial potential of Merrimack's products, product candidates or companion diagnostics.
Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack's views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack's business in general, see the "Risk Factors" section of Merrimack's Annual Report on Form 10-K filed with the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-to-present-at-the-2017-american-association-for-cancer-research-annual-meeting-300429451.html
News Provided by Acquire Media